Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
about
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyondLevosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVEEnoximone echocardiography: a novel test to evaluate left ventricular contractile reserve in patients with heart failure on chronic beta-blocker therapyNovel role of phosphodiesterase inhibitors in the management of end-stage heart failureUse of Inotropic Agents in Treatment of Systolic Heart FailureThe adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series)Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-AnalysisCombined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximoneCardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline.Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure.Role of inotropic agents in the treatment of heart failure.S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with theB-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode.Acute decompensated heart failure update.Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management.Peri-operative beta-blockade and haemodynamic optimisation in patients with coronary artery disease and decreasing exercise capacity presenting for major noncardiac surgery.Management of acute decompensated heart failure.Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlationBeta-blocker therapy in unstable severe heart failure, evidence or experience?Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.Phospholamban overexpression in transgenic rabbitsBeta-blocker therapy of heart failure: an update.The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.β-Receptor blocker influences return of spontaneous circulation and chemical examination in rats during cardiopulmonary resuscitation.Acute Heart Failure TreatmentUse of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure.Preventing LVAD implantation by early short-term mechanical support and prolonged inodilator therapy : A case series with acute refractory cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation and optimised medical strategPathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock.Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.Treatment of acute heart failure in the emergency department.Acute decompensated heart failure: evolving literature and implications for future practice.Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit.Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic EmRisk assessment and anesthetic management of patients with Williams syndrome: a comprehensive review.Moisture Sorption-desorption Characteristics and the Corresponding Thermodynamic Properties of Carvedilol PhosphateRight Ventricular Pressure Overload and Pathophysiology of Growing Porcine Biomodel.Phosphodiesterase-III Inhibitors Amrinone and Milrinone on Epilepsy and Cardiovascular Activities.
P2860
Q24645066-2E781577-AFB6-43FD-B0BE-6B3ECE48C8BBQ24650903-F960F83D-8E92-4B95-8724-5FB5DCA0A359Q24806082-85FC0D4D-13C3-4038-B0E5-2FF468F28C04Q26741100-BEA3132B-D501-41BC-8A9B-145A4CA92CC1Q26774435-00894FCC-72D4-47F9-85DA-5D2ADFE01F95Q26781681-414BADFD-EA4B-4564-9C3E-BFEFCE9B6F1DQ26801321-AC3BDCCE-890E-4F59-9022-21DB00474D9BQ28241758-17DAD734-821A-418D-A8F4-E931D87D63BDQ30318082-4433C55D-BECB-426D-A268-C5755ED19976Q33400219-E41F9538-5DB7-42C8-A478-B260D141A639Q33816527-E84C04EC-9621-4102-AF58-6656C4499A12Q33931999-6B940876-4A88-4331-8E08-7B5C962EADA7Q34830023-7A8E60CE-938E-4500-9BCE-EB123339C8E8Q35000296-A7A54ACC-84C2-48FB-BC48-4D4DD6502454Q35139964-473F924F-E08B-48B3-96F5-FF8708A4822EQ35200873-38BCAE27-B358-4BD1-805C-7BB807A0B505Q35612101-A130AD8C-2B78-4770-8038-240E6269F2D5Q35659776-49155D6C-8AF6-4586-B269-558FAF0F6A5EQ35774994-131CE665-CFCA-49E7-9C5C-CF4A14C6AA7FQ36484589-469E677A-FCCD-4204-9E27-02B6A5F34A4FQ36512551-29904CE9-C303-4A5C-B0B2-44206324006EQ36628719-7A802097-88C4-4E2B-A2CF-B16EB692E9EDQ36723828-37BBD6F9-B45A-4142-9B89-AB782152C3F5Q36765795-72A9F8D3-E3C9-42DB-8EAC-9E13A602D0A2Q36811824-2667208D-409E-4307-BD88-89F616A0E228Q36832816-BA3A9551-7FED-42C9-8E83-9F6E8C2B96B2Q36927823-47B0E82B-34D0-4E48-8225-EB56F9F44B8DQ37291720-41DA5898-EAE2-41DF-9525-33EDF5A592F8Q37605457-2352678F-B076-4942-B597-725C5D9B47D3Q37638446-64893AE5-4E87-4C65-AD7A-ACB8BC6421DEQ37855618-176E1EF0-99EA-4C79-A467-EE0FEA3D4824Q37858515-68BF0649-6AB3-4E7D-845A-8F7D4EFC3C55Q38145265-8530F18E-0A2A-4DFA-96E2-CD66542DB284Q38161451-DBE8CA15-3F65-4552-933A-1A922611ACFBQ38272554-D976E5C2-4190-45C2-BD0B-D04A61C85DDDQ38496703-89BD235A-3632-4F60-A455-1E5F7AF10860Q38604329-6F2BDD21-6D5D-4315-8B11-1645F3CF1649Q38741902-5E5CF1A9-58B5-4756-98DE-E94D437BAC3AQ39456056-6A2CF91A-C6A9-48E7-9F51-0E2E708E0BEFQ41674576-B383E34B-A53E-4D06-AAD8-96410004DED6
P2860
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Beta-blocker therapy influence ...... with metoprolol or carvedilol.
@en
Beta-blocker therapy influence ...... with metoprolol or carvedilol.
@nl
type
label
Beta-blocker therapy influence ...... with metoprolol or carvedilol.
@en
Beta-blocker therapy influence ...... with metoprolol or carvedilol.
@nl
prefLabel
Beta-blocker therapy influence ...... with metoprolol or carvedilol.
@en
Beta-blocker therapy influence ...... with metoprolol or carvedilol.
@nl
P2093
P921
P1476
Beta-blocker therapy influence ...... with metoprolol or carvedilol.
@en
P2093
Alastair D Robertson
Antonio D'Aloia
Claudio Muneretto
Livio Dei Cas
Michael R Bristow
Savina Nodari
P304
P356
10.1016/S0735-1097(02)02134-4
P407
P50
P577
2002-10-01T00:00:00Z